Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to explore the role of congenital mucosal immune system in the airways of patients with COPD including the impact of ILCs (Innate lymphoid cells) on metabolism of epithelial cells.During the research the following methods will be applied: measurement of Volatile Organic Compounds (VOCS), airway epithelial cytology and culture.
ILCs profiles, epithelium metabolism measured by VOCS and microbiome profiling (specific 16S rRNA-16S ribosomal RNA gene-targeted qPCR) will by determined in the airways of patients with COPD after the exacerbation. Microbiome profiling will be based on next generation sequencing (NGS) of the 16S rRNA encoding region.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EX + / ECTS + | Patients suffering COPD exacerbation in last 7 days; active tobacco smokers |
| |
| EX - / ECTS + | Patients without COPD exacerbation in last 6 months; active tobacco smokers |
| |
| EX + / ECTS - | Patients suffering COPD exacerbation in last 7 days; quited tobacco smoking at least 12 months earlier |
| |
| EX - / ECTS - | Patients without COPD exacerbation in last 6 months; quited tobacco smoking at least 12 months earlier |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| airway epithelial smear test | Diagnostic Test | all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture |
| Measure | Description | Time Frame |
|---|---|---|
| percentage of nasal ILCs (Innate lymphoid cells) after COPD exacerbation | The assessment of the nasal mucosa material after COPD exacerbation will include: percentage of ILC1, 2 and 3 cells (immunophenotyping and measurement by flow cytometry) | through study completion, an average of 1 year |
Not provided
Not provided
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
EX (COPD exacerbation) TS (tobacco smoking)
Group: EX + / TS + Patients suffering COPD exacerbation in last 7 days; active tobacco smokers
Group: EX - / TS + Patients without COPD exacerbation in last 6 months; active tobacco smokers
Group: EX + / TS - Patients suffering COPD exacerbation in last 7 days; smoking was stopped a minimum of 12 months before the first visit
Group: EX - / TS - Patients without COPD exacerbation in last 6 months; smoking was stopped a minimum of 12 months before the first visit
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Paweł Majak | Contact | 600621878 | pmajak@o2.pl |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland | Recruiting | Lodz | 90-153 | Poland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000073869 | Tobacco Smoking |
| ID | Term |
|---|---|
| D012907 | Smoking |
| D001519 | Behavior |
| D064424 | Tobacco Use |
Not provided
Not provided
Not provided
Not provided
Not provided
|